{
    "organizations": [],
    "uuid": "1e0508bd1bfa981652158fc67cbd16c228670cfe",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acelrx-plans-to-resubmit-the-dsuvi/brief-acelrx-plans-to-resubmit-the-dsuvia-new-drug-application-in-q2-idUSASB0C9J8",
    "ord_in_thread": 0,
    "title": "BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Acelrx Pharmaceuticals Inc:\n* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018\n* ACELRX PHARMACEUTICALS INC - ‍INTENDS TO RESUBMIT NDA IN Q2 OF 2018 AFTER COMPLETION OF HF STUDY​\n* ACELRX PHARMACEUTICALS - ‍RECEIPT OF OFFICIAL JANUARY 2018 TYPE A MEETING MINUTES FROM U.S. FDA RELATING TO ACELRX’S DSUVIA NDS\n* ACELRX PHARMACEUTICALS INC - ‍ACELRX PROPOSED POTENTIAL RESOLUTIONS FOR TWO MAIN POINTS IDENTIFIED IN CRL RECEIVED FROM FDA IN OCTOBER 2017​\n* ACELRX PHARMACEUTICALS INC - CO PROPOSED INSTEAD TO REDUCE MAXIMUM DOSE IN LABEL TO NOT EXCEED 12 TABLETS WITHIN A 24-HOUR PERIOD\n* ACELRX PHARMACEUTICALS INC - CO SUBMITTED TO FDA UPDATED DFU, AND A REVISED PROTOCOL FOR HF STUDY REQUIRED TO VALIDATE EFFECTIVENESS OF DFU CHANGES​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:22:00.000+02:00",
    "crawled": "2018-03-09T14:09:38.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "announces",
        "receipt",
        "type",
        "fda",
        "meeting",
        "minute",
        "plan",
        "resubmit",
        "dsuvia",
        "new",
        "drug",
        "application",
        "q2",
        "acelrx",
        "pharmaceutical",
        "inc",
        "resubmit",
        "nda",
        "q2",
        "completion",
        "hf",
        "acelrx",
        "pharmaceutical",
        "official",
        "january",
        "type",
        "meeting",
        "minute",
        "fda",
        "relating",
        "acelrx",
        "dsuvia",
        "nd",
        "acelrx",
        "pharmaceutical",
        "inc",
        "proposed",
        "potential",
        "resolution",
        "two",
        "main",
        "point",
        "identified",
        "crl",
        "received",
        "fda",
        "october",
        "acelrx",
        "pharmaceutical",
        "inc",
        "co",
        "proposed",
        "instead",
        "reduce",
        "maximum",
        "dose",
        "label",
        "exceed",
        "tablet",
        "within",
        "period",
        "acelrx",
        "pharmaceutical",
        "inc",
        "co",
        "submitted",
        "fda",
        "updated",
        "dfu",
        "revised",
        "protocol",
        "hf",
        "study",
        "required",
        "validate",
        "effectiveness",
        "dfu",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}